Bio-Rad Laboratories Stock Price, News & Analysis (NYSE:BIO)

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bio-Rad Laboratories in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BIO shares.
View BIO analyst ratings or view top-rated stocks.

3 brokers have issued 1 year price targets for Bio-Rad Laboratories' shares. Their BIO share price targets range from $524.00 to $550.00. On average, they expect the company's stock price to reach $533.00 in the next twelve months. This suggests a possible upside of 73.6% from the stock's current price.
View analysts price targets for BIO or view top-rated stocks among Wall Street analysts.

Bio-Rad Laboratories' stock was trading at $420.49 at the beginning of the year. Since then, BIO shares have decreased by 27.0% and is now trading at $307.00.
View the best growth stocks for 2023 here.

Bio-Rad Laboratories saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 572,100 shares, an increase of 36.9% from the October 31st total of 418,000 shares. Based on an average daily volume of 235,900 shares, the short-interest ratio is currently 2.4 days. Currently, 2.8% of the company's shares are short sold.
View Bio-Rad Laboratories' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 15th 2024.
View our BIO earnings forecast.

Bio-Rad Laboratories, Inc. (NYSE:BIO) announced its earnings results on Thursday, October, 26th. The medical research company reported $2.33 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.87 by $0.54. The medical research company had revenue of $632.10 million for the quarter, compared to analysts' expectations of $689.50 million. Bio-Rad Laboratories had a positive trailing twelve-month return on equity of 3.91% and a negative net margin of 5.86%. The firm's revenue was down 7.1% compared to the same quarter last year. During the same period last year, the firm posted $2.60 earnings per share.
Read the conference call transcript.

ETFs with the largest weight of Bio-Rad Laboratories (NYSE:BIO) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM), Harbor Health Care ETF (MEDI), Putnam BioRevolution ETF (SYNB), Principal Healthcare Innovators ETF (BTEC), Invesco S&P 500 Equal Weight Health Care ETF (RYH), Invesco S&P 500 Equal Weight Health Care ETF (RSPH), ROBO Global Healthcare Technology and Innovation ETF (HTEC) and First Trust Indxx Medical Devices ETF (MDEV).

325 employees have rated Bio-Rad Laboratories Chief Executive Officer Norman Schwartz on Glassdoor.com. Norman Schwartz has an approval rating of 84% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Rad Laboratories investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AbbVie (ABBV), NVIDIA (NVDA), Broadcom (AVGO), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), Alibaba Group (BABA) and Intel (INTC).

Bio-Rad Laboratories' stock is owned by a variety of institutional and retail investors. Top institutional investors include Veritas Asset Management LLP (3.83%), Brown Advisory Inc. (3.29%), Westfield Capital Management Co. LP (1.24%), Earnest Partners LLC (1.21%), Invesco Ltd. (1.18%) and Massachusetts Financial Services Co. MA (1.11%). Insiders that own company stock include Ajit Ramalingam, Annette Tumolo, Ilan Daskal, Michael Crowley, Timothy S Ernst and Timothy S Ernst.
View institutional ownership trends.

Shares of BIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.